RARA CRAFT DATABASE for FDA Medical Devices
PMAP210011

FDA DEVICE FACTS

xT CDx

Tempus Labs, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

AI/ML
DECISION DATEApril 28, 2023PRODUCT CODEPQPCLINICAL AREAPathology

Indications for use

xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for detection of substitutions (single-nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite-instability (MSI) status, using DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor-tissue specimens and DNA isolated from matched normal blood or saliva specimens from previously diagnosed cancer patients with solid malignant neoplasms. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with targeted therapies listed in the Companion Diagnostic Indications table in accordance with approved therapeutic-product labeling. The approved companion-diagnostic indications are: colorectal cancer with KRAS wild type (absence of mutations in codons 12 or 13) for Erbitux (cetuximab); and colorectal cancer with KRAS wild type (absence of mutations in exons 2, 3, or 4) and NRAS wild type (absence of mutations in exons 2, 3, or 4) for Vectibix (panitumumab). Additionally, xT CDx is intended to provide tumor-mutation profiling for use by qualified healthcare professionals in accordance with professional oncology guidelines for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, Illinois.

Tables from the FDA document

Tumor TypeBiomarker(s) DetectedTherapy
Colorectal cancer (CRC)KRAS wild type (absence of mutations in codons 12 or 13)Erbitux (cetuximab)
Colorectal cancer (CRC)KRAS wild type (absence of mutations in exons 2, 3, or 4) and NRAS wild type (absence of mutations in exons 2, 3, or 4)Vectibix (panitumumab)

Tables marked from the FDA document were reconstructed automatically. Check the original FDA document (links at the end of this page) for authoritative values.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026